CRVS
NASDAQ · Biotechnology
Corvus Pharmaceuticals Inc
$13.26
+0.07 (+0.53%)
Open$13.24
Previous Close$13.19
Day High$13.37
Day Low$12.81
52W High$26.95
52W Low$4.05
Volume—
Avg Volume769.2K
Market Cap1.15B
P/E Ratio—
EPS$-0.53
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+242.4% upside
Current
$13.26
$13.26
Target
$45.40
$45.40
$29.32
$45.40 avg
$54.46
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 641.17M | 595.25M | 563.38M |
| Net Income | 40.80M | 37.35M | 36.12M |
| Profit Margin | 6.4% | 6.3% | 6.4% |
| EBITDA | 52.52M | 47.56M | 47.46M |
| Free Cash Flow | 29.89M | 29.19M | 29.71M |
| Rev Growth | +19.0% | -0.6% | +17.7% |
| Debt/Equity | 0.54 | 0.42 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |